Stony Brook University

Running trials

• Recruiting

  Controlled Trial of Hydrogen Water as a Treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

  NCT07753122· Source

• Recruiting

  Behavioral Activation for Treatment of Depression in Autistic Adolescents With Below Average Intelligence

  NCT07812870· Source

• Recruiting

  A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications

  NCT07330258· Source

• Recruiting

  LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

  NCT07415044· Phase 2· Source

• Recruiting

  Hydrogen Water Intervention With Heart Rate Variability as an Outcome Biomarker in ME/CFS

  NCT07009691· Source

• Active, not recruiting

  Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

  NCT06760637· Phase 3· Source

• Recruiting

  Testing a Brief Motivational Intervention to Increase Physical Activity for Cancer Survivors

  NCT07215091· Source

• Active, not recruiting

  First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

  NCT06239467· Phase 1· Source

• Active, not recruiting

  A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

  NCT06111235· Phase 3· Source

• Recruiting

  A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT05730036· Phase 3· Source

• Recruiting

  The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

  NCT05836987· Phase 3· Source

• Active, not recruiting

  Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

  NCT04452591· Phase 3· Source

• Active, not recruiting

  TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

  NCT04485013· Phase 1· Source

• Active, not recruiting

  A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma

  NCT04268498· Phase 2· Source

• Recruiting

  Stroke Thrombectomy and Aneurysm Registry

  NCT04994756· Source

• Active, not recruiting

  Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

  NCT02665065· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Long COVID and ME/CFS2 recruiting
• Stroke2 recruiting
• Atrial fibrillation1 recruiting
• Autism1 recruiting
• Childhood cancers1 recruiting
• Parkinson disease1 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Withdrawn

  A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

  NCT06205290· Phase 3· Source

• Terminated

  Deep rTMS Modulating Insula Synaptic Density and Smoking Behavior in Schizophrenia

  NCT05724810· Source

• Completed

  Abbott i-STAT High Sensitivity Troponin I Study

  NCT05629572· Source

• Completed

  Distal Ischemic Stroke Treatment With Adjustable Low-profile Stentriever

  NCT05152524· Source

• Terminated

  Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer

  NCT04958785· Phase 2· Source

• Completed

  A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial

  NCT04847557· Phase 3· Source

• Completed

  A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia

  NCT04457310· Phase 2· Source

• Completed

  Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer

  NCT03941093· Phase 3· Source

• Completed

  Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

  NCT03778931· Phase 3· Source

• Completed

  MIND: Artemis in the Removal of Intracerebral Hemorrhage

  NCT03342664· Source

• Completed

  A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

  NCT02684006· Phase 3· Source

• Completed

  Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial

  NCT02089217· Source